Definition:

Zilretta™ (triamcinolone acetonide extended-release injection) is an extended-release synthetic corticosteroid indicated as an intraarticular injection for the management of osteoarthritis pain of the knee. It is not intended for repeat administration or for patients who are allergic to corticosteroids, triamcinolone acetonide, or any other component of the product.

Dosing:

Max Units (per dose and over time):

- 35 billable units per knee per lifetime

Guideline:

Zilretta™ (triamcinolone acetonide extended-release injection) is considered medically when the following criteria are met:

- Diagnosis of osteoarthritis of the knee; AND
- Prescribed by or in consultation with a rheumatologist or an orthopedist; AND
- Patient is 18 years of age or older; AND
- Failure of ≥ 2 week trial of one of the following (a or b), unless contraindicated or clinically significant adverse effects are experienced:
• Oral nonsteroidal anti-inflammatory drug (NSAID) at continuous therapeutic dosing (prescription strength); OR
  • Topical NSAID if member is ≥ 75 years old or unable to take an oral NSAID; AND
  • History of a positive, but inadequate, response to at least one other intraarticular glucocorticoid injection (i.e. intra-articular immediate-release triamcinolone) for the knee defined as:
    • inadequate pain relief; OR
    • frequent need of rescue medications such as NSAIDs or opioids; OR
    • need to decrease or inability to increase activity levels; OR
    • adequate pain relief accompanied by steroid-induced hyperglycemia

Limitations/Exclusions

• Approval will be granted for a maximum of 1 dose of Zilretta (triamcinolone acetonide extended-release injection) per knee per lifetime
• Patients who are allergic to corticosteroids, triamcinolone acetonide, or any other component of the product.
• Coverage cannot be renewed

Revisions

10/31/2019
Under Guideline, added history of a positive, but inadequate, response to at least one other intraarticular glucocorticoid injection (i.e. intra-articular immediate-release triamcinolone)
- Under Limitations/Exclusions, added patients who are allergic to corticosteroids, triamcinolone acetonide, or any other component of the product
- updated the Zilretta link in the reference https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208845s000lbl.pdf
Added J3304 and removed Q9993 from Applicable Procedure Codes.

12/3/2018
Added J3304 and removed Q9993 from Applicable Procedure Codes.

Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J3304</td>
<td>Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg</td>
</tr>
</tbody>
</table>

Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M17.0</td>
<td>Bilateral primary osteoarthritis of knee</td>
</tr>
<tr>
<td>M17.11</td>
<td>Unilateral primary osteoarthritis, right knee</td>
</tr>
<tr>
<td>M17.12</td>
<td>Unilateral primary osteoarthritis, left knee</td>
</tr>
<tr>
<td>M17.2</td>
<td>Bilateral post-traumatic osteoarthritis of knee</td>
</tr>
<tr>
<td>M17.31</td>
<td>Unilateral post-traumatic osteoarthritis, right knee</td>
</tr>
<tr>
<td>M17.32</td>
<td>Unilateral post-traumatic osteoarthritis, left knee</td>
</tr>
<tr>
<td>M17.4</td>
<td>Other bilateral secondary osteoarthritis of knee</td>
</tr>
<tr>
<td>M17.5</td>
<td>Other unilateral secondary osteoarthritis of knee</td>
</tr>
</tbody>
</table>

Reference:
